Ami Fadia
Stock Analyst at Needham
(4.46)
# 295
Out of 5,050 analysts
402
Total ratings
51.78%
Success rate
20.54%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $66 → $72 | $61.01 | +18.01% | 27 | Nov 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $28 → $29 | $22.57 | +28.49% | 12 | Nov 6, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $154 | $138.15 | +11.47% | 17 | Nov 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $170 → $184 | $152.37 | +20.76% | 16 | Oct 29, 2025 | |
| ALKS Alkermes | Maintains: Buy | $43 → $44 | $32.89 | +33.78% | 4 | Oct 29, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Buy | $6 → $8 | $2.56 | +212.50% | 10 | Oct 28, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | n/a | $18.69 | - | 37 | Oct 22, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $80 → $250 | $168.22 | +48.61% | 13 | Oct 16, 2025 | |
| GHRS GH Research | Initiates: Buy | $19 | $13.50 | +40.74% | 1 | Oct 13, 2025 | |
| ATAI Atai Beckley | Initiates: Buy | $12 | $4.36 | +175.23% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $11.70 | +139.32% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $6.89 | +59.65% | 20 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $96 | $95.23 | +0.81% | 31 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $41 | $31.43 | +30.45% | 38 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $155.51 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $202 | $131.16 | +54.01% | 34 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $16 | $9.73 | +64.44% | 21 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $14.82 | - | 23 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $22.12 | +58.23% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $6.44 | +350.31% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $15.71 | +1,936.92% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.04 | +240.29% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.60 | +3,619.62% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $14.44 | +336.29% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $23.97 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.10 | +1,900.00% | 4 | Jan 3, 2018 |
Revolution Medicines
Nov 6, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $61.01
Upside: +18.01%
ACADIA Pharmaceuticals
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $22.57
Upside: +28.49%
Axsome Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $154
Current: $138.15
Upside: +11.47%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $170 → $184
Current: $152.37
Upside: +20.76%
Alkermes
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $32.89
Upside: +33.78%
Neumora Therapeutics
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $2.56
Upside: +212.50%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: n/a
Current: $18.69
Upside: -
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $80 → $250
Current: $168.22
Upside: +48.61%
GH Research
Oct 13, 2025
Initiates: Buy
Price Target: $19
Current: $13.50
Upside: +40.74%
Atai Beckley
Oct 13, 2025
Initiates: Buy
Price Target: $12
Current: $4.36
Upside: +175.23%
Oct 13, 2025
Initiates: Buy
Price Target: $28
Current: $11.70
Upside: +139.32%
Sep 30, 2025
Reiterates: Buy
Price Target: $11
Current: $6.89
Upside: +59.65%
Sep 29, 2025
Downgrades: Hold
Price Target: $96
Current: $95.23
Upside: +0.81%
Sep 24, 2025
Maintains: Buy
Price Target: $48 → $41
Current: $31.43
Upside: +30.45%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $155.51
Upside: -
Aug 28, 2025
Reiterates: Buy
Price Target: $202
Current: $131.16
Upside: +54.01%
Aug 6, 2025
Maintains: Buy
Price Target: $18 → $16
Current: $9.73
Upside: +64.44%
Jun 17, 2025
Reiterates: Hold
Price Target: n/a
Current: $14.82
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $22.12
Upside: +58.23%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $6.44
Upside: +350.31%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $15.71
Upside: +1,936.92%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.04
Upside: +240.29%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.60
Upside: +3,619.62%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $14.44
Upside: +336.29%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $23.97
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.10
Upside: +1,900.00%